Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Pulmonary Arterial Hypertension Secondary to COPD
IRCT20250908067192N1Phase 2Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of empagliflozin in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH), sponsored by Shahrekord University of Medical Sciences. Started Nov 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)
Beyond the preview
Go deeper on IRCT20250908067192N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250908067192N1.